Skip to Content

Loteprednol / tobramycin ophthalmic Disease Interactions

There are 2 disease interactions with loteprednol / tobramycin ophthalmic:

Major

Ophthalmic Corticosteroids (Includes Loteprednol/tobramycin ophthalmic) ↔ Ocular Infections

Severe Potential Hazard, High plausibility

Applies to: Ocular Infection

The use of ophthalmic corticosteroids is contraindicated in most viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella; fungal diseases of ocular structures; mycobacterial infections, including tuberculosis, of the eye; and any acute, purulent, untreated ocular infections. Corticosteroids may decrease host resistance to infectious agents, thus prolonging the course and/or exacerbating the severity of the infection while encouraging the development of new or secondary infection. In addition, administration of ophthalmic corticosteroids in severe ocular disease, especially acute herpes simplex keratitis, may lead to excessive corneal and scleral thinning, increasing the risk for perforation. In less serious ocular infections, therapy with ophthalmic corticosteroids may be administered but only with caution and accompanied by appropriate antimicrobial agents. Besides compromising host immune response, corticosteroids may also mask the symptoms of infection, thus hindering the recognition of potential ineffectiveness of the antibiotic therapy. If infection does not improve or becomes worse during administration of an ophthalmic corticosteroid, the drug should be discontinued and other appropriate therapy initiated.

References

  1. "Product Information. FML Ophthalmic Suspension (fluoromethalone ophthalmic)." Allergan Inc, Irvine, CA.
  2. "Product Information. Lotemax (loteprednol ophthalmic)." Bausch and Lomb, Tampa, FL.
  3. "Product Information. Pred Forte (prednisolone ophthalmic)." Allergan Inc, Irvine, CA.
  4. "Product Information. HMS (medrysone ophthalmic)." Allergan Inc, Irvine, CA.
  5. "Product Information. Decadron Ocumeter (dexamethasone ophthalmic)." Merck & Co, Inc, West Point, PA.
  6. "Product Information. Vexol (rimexolone ophthalmic)." Alcon Laboratories Inc, Fort Worth, TX.
View all 6 references
Major

Ophthalmic Corticosteroids (Includes Loteprednol/tobramycin ophthalmic) ↔ Ocular Toxicities

Severe Potential Hazard, High plausibility

Applies to: Cataracts, Glaucoma/Intraocular Hypertension

Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves. Therapy with ophthalmic corticosteroids should be administered cautiously in patients with a history of cataracts, glaucoma, or increased intraocular pressure. If these agents are used for more than 10 days, the manufacturers recommend that intraocular pressure be routinely monitored, including in children. The equatorial and posterior subcapsular portions of the lens should be examined for changes.

References

  1. Foster CS, Alter G, Debarge LR, Raizman MB, Crabb JL, Santos CI, Feiler LS, Friedlaender MH "Efficacy and safety of rimexolone 1% ophthalmic suspension vs 1% prednisolone acetate in the treatment of uveitis." Am J Ophthalmol 122 (1996): 171-82
  2. Francois J "Corticosteroid glaucoma." Ann Ophthalmol 9 (1977): 1075-80
  3. "Product Information. Vexol (rimexolone ophthalmic)." Alcon Laboratories Inc, Fort Worth, TX.
  4. "Product Information. Lotemax (loteprednol ophthalmic)." Bausch and Lomb, Tampa, FL.
  5. "Product Information. Pred Forte (prednisolone ophthalmic)." Allergan Inc, Irvine, CA.
  6. Seale JP, Compton MR "Side-effects of corticosteroid agents." Med J Aust 144 (1986): 139-42
  7. "Product Information. HMS (medrysone ophthalmic)." Allergan Inc, Irvine, CA.
  8. "Product Information. Decadron Ocumeter (dexamethasone ophthalmic)." Merck & Co, Inc, West Point, PA.
  9. Kitazawa Y "Increased intraocular pressure induced by corticosteroids." Am J Ophthalmol 82 (1976): 492-5
  10. Leibowitz HM, Bartlett JD, Rich R, Mcquirter H, Stewart R, Assil K "Intraocular pressure-raising potential of 1.0% rimexolone in patients responding to corticosteroids." Arch Ophthalmol 114 (1996): 933-7
  11. Butcher JM, Austin M, McGalliard J, Bourke RD "Bilateral cataracts and glaucoma induced by long term use of steroid eye drops." BMJ 309 (1994): 43
  12. Godel V, Regenbogen L, Stein R "On the mechanism of corticosteroid-induced ocular hypertension." Ann Ophthalmol 10 (1978): 191-6
  13. "Product Information. FML Ophthalmic Suspension (fluoromethalone ophthalmic)." Allergan Inc, Irvine, CA.
View all 13 references

loteprednol / tobramycin ophthalmic drug Interactions

There are 9 drug interactions with loteprednol / tobramycin ophthalmic

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide